Orthofix cuts 2026 outlook after third-quarter revenue miss

By Amara Osei

Orthofix Medical cut its 2026 net-sales outlook to $825 million–$830 million, below the roughly $851 million analyst consensus, after third-quarter revenue came in at $207.86 million against $210.52 million expected.

On Monday’s earnings call, executives attributed a 5% fall in U.S. spine fixation sales to market softness, supplier delays and instrument-set constraints. The company now expects 2026 adjusted EBITDA of $86 million–$88 million.

Why did third-quarter revenue miss expectations?

Orthofix issued its results Monday. On the headline comparison, it reported a $0.15 loss per share against a $0.26 loss expected, a $0.11 beat. A separate earnings recap listed adjusted earnings of $0.18 per share, above a $0.11 consensus, and said the GAAP loss per share also was narrower than analysts expected.

Revenue of $207.86 million fell below the $210.52 million estimate. Orthofix also posted a negative 14.05% return on equity and a negative 7.41% net margin. Revenue still fell short.

The bottom line improved, but the sales shortfall and weaker core spine market kept the quarter below expectations.

What held up outside spine?

Limb Reconstruction sales rose 9%, while Therapeutic Solutions increased 4%. U.S. biologics sales were roughly flat sequentially. Management said the segment had "returned to year-over-year growth in October."

Adjusted EBITDA rose to $26 million from $24.6 million a year earlier, even as spine revenue declined. The balance was uneven.

Limb reconstruction and therapeutics supplied enough growth to lift adjusted EBITDA despite weakness in Orthofix’s largest business.

What changes in 2026 and 2027?

Management is concentrating spine resources on core distributors, which generate about 80% of U.S. spinal implant revenue, and said supplier fixes are underway.

• The company said the VIRATA open-procedure system is expected "to launch in the fourth quarter." Management sees the business as better positioned for 2027, although the recovery is expected to take time.
• A European distributor arrangement should add about $15 million to 2026 sales, mostly in the fourth quarter. Related cash receipts are not expected until 2027, creating a temporary cash-timing headwind.
• European MDR requirements are expected to create an approximately $22 million spine-sales headwind in 2027.

Cash arrives later. Management expects more 2026 revenue, but delayed collections and European regulatory costs constrain the 2027 recovery.

How did the market and analysts react?

Orthofix shares traded up 0.4% and opened Tuesday at $7.90. The 50-day moving average was $9.25, while the 200-day average was $10.96. Its quick ratio was 1.67, current ratio 2.84, and debt-to-equity ratio 0.55.

Market capitalization stood at $321.77 million, the P/E ratio was -5.13, and beta was 0.66. The 12-month range ran from $6.52 to $16.42.

On Tuesday, November 3, Weiss Ratings moved Orthofix from a "sell (d-)" rating to a "sell (e+)" rating. Canaccord Genuity Group cut its target price from $18.00 to $13.00 and set a Buy rating in a research note on Monday, August 10.

Three equities analysts rate the stock Buy, one rates it Hold and one rates it Sell. MarketBeat lists a consensus rating of Hold and an average price target of $14.75. Ratings remain divided.

A separate report flagged FDA reclassification of bone growth stimulators as a competitive risk. Orthofix could face pressure on its market position and margins if the regulatory change increases competition.

The stock opened below both major moving averages, while regulatory risk and uneven analyst views constrain a clear market verdict.

What does Orthofix sell?

Orthofix develops, manufactures and distributes spinal and orthopedic devices designed to treat spinal disorders, support bone healing, and address orthopedic trauma and related musculoskeletal conditions.

Its portfolio includes spinal fixation and interbody systems, biologics and bone-grafting products, bone growth stimulation devices, and technologies for spinal motion preservation and deformity correction.

Orthofix remains exposed to spine procedures and bone-growth-stimulator rules, making new-product execution and distributor performance central to its outlook.